04:46 PM EDT, 07/08/2025 (MT Newswires) -- NurExone Biologic ( NRXBF ) after close of trade Tuesday said new preclinical results demonstrate all small animals treated with a higher dose of ExoPTEN regained motor function after spinal cord injury.

According to a company statement, by using the CatWalk XT system, researchers assessed ExoPTEN's effect on the animals' ability to walk, with all animals in the higher-dose group demonstrating "measurable gait recovery," in contrast to one animal in the untreated group which exhibited minimal stepping.

"This is a significant milestone for our program," said Director of Research and Development, Dr. Tali Kizhner. "Seeing the animals regain the ability to walk, with measurable improvement in locomotion function, is incredibly exciting. The CatWalk XT provided us with objective data that strengthens the scientific foundation for ExoPTEN's potential to restore function after an acute spinal cord injury."

The company shares closed down $0.01 to $0.67 on the TSX Venture Exchange.